Ichinose et al., 1987 - Google Patents
Increase of catecholamines in mouse brain by systemic administration of γ‐glutamyl l‐3, 4‐dihydroxyphenylalanineIchinose et al., 1987
- Document ID
- 11619960356844217148
- Author
- Ichinose H
- Togari A
- Suzuki H
- Kumagai H
- Nagatsu T
- Publication year
- Publication venue
- Journal of neurochemistry
External Links
Snippet
We investigated the effect of systemic administration of γ‐glutamyl L‐3, 4‐ dihydroxyphenylalanine (γ‐Glu‐DOPA) on catecholamine contents in the brain. γ‐Glu‐ DOPA was transformed to dopamine (DA) in vitro with brain homogenate by the sequential …
- 210000004556 Brain 0 title abstract description 61
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl group being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epihephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Karoum et al. | Brain concentrations of biogenic amine metabolites in acutely treated and ethanol‐dependent rats | |
| Curtius et al. | Mass fragmentography of dopamine and 6-hydroxydopamine: application to the determination of dopamine in human brain biopsies from the caudate nucleus | |
| Wilk et al. | gamma-Glutamyl dopa: a kidney-specific dopamine precursor. | |
| Lovenberg et al. | Tryptophan hydroxylation in mammalian systems | |
| US6372793B1 (en) | Method for treatment of a neurological disease characterized by impaired neuromodulator function | |
| Ichinose et al. | Increase of catecholamines in mouse brain by systemic administration of γ‐glutamyl l‐3, 4‐dihydroxyphenylalanine | |
| Meister et al. | Diminished phenylketonuria in phenylpyruvic oligophrenia after administration of L-glutamine, L-glutamate or L-asparagine | |
| Gluck et al. | Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson’s activity | |
| JP2004105190A (en) | Method of testing a drug for its activity in maintaining, preventing or restoring neuronal function | |
| Hinterberger et al. | Catecholamine metabolism during oral administration of Levodopa: effects of the medication in Parkinson's disease | |
| Abe et al. | Stereoselective effect of (R)-and (S)-1-methyl-1, 2, 3, 4-tetrahydroisoquinolines on a mouse model of Parkinson’s disease | |
| Edwards et al. | Conversion of 3, 4‐dihydroxyphenylalanine and deuterated 3, 4‐dihydroxyphenylalanine to alcoholic metabolites of catecholamines in rat brain | |
| Hiroshi et al. | Effects of heterocyclic amines in food on dopamine metabolism in nigro-striatal dopaminergic neurons | |
| Edwards | Possible role of octopamine and tyramine in the antihypertensive and antidepressant effects of tyrosine | |
| Fell et al. | The labelling of urinary acids after oral doses of deuterated L-phenylalanine and L-tyrosine in normal subjects. Quantitative studies with implications for the deuterated phenylalanine load test in phenylketonuria | |
| Pettibone et al. | d-Amphetamine reduces striatal substance P concentrations by presynaptic release of dopamine | |
| Brannan et al. | Intracerebral dialysis monitoring of striatal dopamine release and metabolism in response to L-DOPA | |
| Lindqvist et al. | Attempts to measure endogenous levels of dopa and 5-hydroxytryptophan in rat brain | |
| Algeri et al. | Biochemical effects of treatment with oral contraceptive steroids on the dopaminergic system of the rat | |
| Becker et al. | Delta‐aminolevulinic acid uptake by rabbit brain cerebral cortex | |
| Watanabe et al. | Ammonia detoxification by accelerated oxidation of branched chain amino acids in brains of acute hepatic failure rats | |
| Smith | UPTAKE OF 5‐HYDROXY [14C] TRYPTOPHAN BY RAT AND DOG BRAIN SLICES | |
| Magnussen et al. | Plasma Accumulation and Metabolism of Orally Administered Single Dose L‐5‐Hydroxytryptophan in Man | |
| McQuade | Analysis and the effects of some drugs on the metabolism of phenylethylamine and phenylacetic acid | |
| Semba et al. | The effects of L-threo-dihydroxyphenylserine on norepinephrine metabolism in rat brain |